1-20 of 32
Martine Gardembas, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Franck E Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnès Guerci-Bresler, MD PhD, Aude Charbonnier, MD PhD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD PhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, MD PhD, Denis Guyotat, MD PhD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Eric Deconinck, MD PhD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Alexandre Deloire, CRA, Stephane Morisset, BioStat, Madeleine Etienne, CRA, Delphine Rea, MD, Stephanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 494.
https://doi.org/10.1182/blood-2019-123674
Published: 2019
Journal Articles

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Laurence Legros, MD PhD, Franck E Nicolini, MDPhD, Gabriel Etienne, MD PhD, Philippe Rousselot, MDPhD, Delphine Rea, MD, Stephane Giraudier, MD PhD, Agnès Guerci, MD PhD, Francoise Huguet, MD, Martine Gardembas, MD, Jean-Christophe Ianotto, MD PhD, Martine Escoffre-Barbe, MD, Valerie Coiteux, MD, Bruno Varet, MD, Stephane Morisset, BioStat, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 28.
https://doi.org/10.1182/blood-2019-123719
Published: 2019
Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 30.
https://doi.org/10.1182/blood-2019-124408
Published: 2019
Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Marie Balsat, MD, Vincent Alcazer, MD, Gabriel Etienne, MD PhD, Gaelle Fossard, MD, Francoise Huguet, MD, Marc G. Berger, MD PhD, Emilie Cayssials, MD, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Hyacinthe Johnson-Ansah, MD, Viviane Dubruille, MD, Laurence Legros, MD PhD, Lydia Roy, MD, Alain Jacques Delmer, MD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Fabrice Larosa, Stephane Courby, MD, Shanti Ame, MD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Delphine Rea, MD, Franck Emmanuel Nicolini, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 48.
https://doi.org/10.1182/blood-2018-99-113058
Published: 2018
Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Franck Emmanuel Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MDPhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD PhD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, Denis Guyotat, Jean-Christophe Ianotto, MD, Martine Gardembas, MD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Verane Schwiertz, PharmD, Stephane Morisset, Stat, Madeleine Etienne, CRA, Delphine Rea, MD PhD, Stephanie Dulucq, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 899.
https://doi.org/10.1182/blood.V130.Suppl_1.899.899
Published: 2017
Journal Articles

Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort

Marc G Berger, MD PhD Professor, Bruno Pereira, PhD, Charlotte Oris, PhD, Sandrine Saugues, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Laurence Legros, MD, Martine Escoffre-Barbe, Franck E. Nicolini, MD PhD, Philippe Rousselot, MD PhD Professor, Delphine Rea, MD PhD, Joelle Guilhot, PhD, Marie Zénut, MD PhD, Agnès Guerci, MD PhD, Stephane Giraudier, MD PhD Professor, Francois-Xavier Mahon, MD PhD Professor
Journal: Blood
Blood (2015) 126 (23): 137.
https://doi.org/10.1182/blood.V126.23.137.137
Published: 2015
Journal Articles

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

Philippe Rousselot, MD PhD, Hyacinthe Johnson-Ansah, MD, Françoise Huguet, MD, Laurence Legros, MD, Martine Escoffre-Barbe, Martine Gardembas, MD, Pascale Cony-Makhoul, MD, Valérie Coiteux, MD, Laurent Sutton, MD, Wajed Abarah, MD, Camille Pouaty, MD, Jean Michel Pignon, MD, Bachra Choufi, MD, Sorin Visanica, MD, Bénédicte Deau, MD, Stephane Bouchet, MDPhD, Francois Guilhot, MD, Francois-Xavier Mahon, MD PhD Professor, Laure Morisset, Jean-Michel Cayuela, Benjamin Maneglier, MD
Journal: Blood
Blood (2015) 126 (23): 133.
https://doi.org/10.1182/blood.V126.23.133.133
Published: 2015
Journal Articles

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

Lydia ROY, MD, Jean-Claude Chomel, PharmD PhD, Joelle Guilhot, PhD, Agnes Guerci-Bresler, MD, Martine Escoffre-Barbe, Stéphane Giraudier, MD PhD, Aude Charbonnier, Viviane Dubruille, MD, Françoise Huguet, Hyacinthe Johnson-Ansah, MD, Pascal Lenain, MD, Shanti Amé, MD, Gabriel Etienne, MD PhD, Franck E. Nicolini, Delphine Rea, MD PhD, Pascale Cony-Makhoul, MD, Stephane Courby, MD, Jean-Christophe Ianotto, MD, Laurence Legros, MD, Martine Delain, MD, Valérie Coiteux, MD, Eric Hermet, MD, Martine Gardembas, MD, Mathieu Molimard, MD PhD, Jean-Michel Cayuela, Marie Thibaud, CRA, Sophie Duranton, PharmD, Francois-Xavier Mahon, MD PhD, Philippe Rousselot, MD PhD Professor, Francois Guilhot, MD
Journal: Blood
Blood (2015) 126 (23): 134.
https://doi.org/10.1182/blood.V126.23.134.134
Published: 2015
Journal Articles

Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results

Franck E. Nicolini, MD PhD, Gabriel Etienne, MD PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, MD, Laurence Legros, MD, Stéphane Giraudier, MD PhD, Valérie Coiteux, MD, Agnes Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, Shanti Amé, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD PhD, Marie-Claude Gagnieu, PharmD, PhD, Stéphane Morisset, Stat, Christine Pivot, PharmD, Madeleine Etienne, CRA, Francois Guilhot, MD, Stéphanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD Professor
Journal: Blood
Blood (2015) 126 (23): 1578.
https://doi.org/10.1182/blood.V126.23.1578.1578
Published: 2015
Journal Articles

GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis

Philippe Guardiola, MD, Corentin Orvain, Nick C.P. Cross, PhD, Martine Gardembas, MD, Marc Spentchian, MD, Estelle Pedrono, PhD, Diane Lambert, PhD, Anne Coutolleau, Anne Bouvier, MD, Odile Blanchet, MDPhD, Nicole Piard, MD, Norbert Ifrah, MD PhD, Frank Giles, MD MB, FRCPI, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, Philippe Rousselot, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2768.
https://doi.org/10.1182/blood.V126.23.2768.2768
Published: 2015
Journal Articles

Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc

Delphine Rea, MD PhD, Franck E. Nicolini, MD PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Francois Guilhot, MD, Martine Gardembas, MD, Agnès Guerci, MD, Valérie Coiteux, MD, Laurence Legros, MD PhD, Gaelle Guillerm, MD, Jean Michel Pignon, MD, Stephane Giraudier, MD PhD, Gabriel Etienne, Bruno Villemagne, MD, Martine Escoffre, MD, Aude Charbonnier, MD PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2014) 124 (21): 811.
https://doi.org/10.1182/blood.V124.21.811.811
Published: 2014
Journal Articles

Characteristics and Outcomes of Unselected Adolescents and Young Adults Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Stéphanie Bernardin, Franck E. Nicolini, MD PhD, Delphine Rea, MD PhD, Mael Haiblig, MD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, P Cony-Makhoul, MD, Martine Escoffre-Barbe, MD, Stephane Giraudier, Agnes Guerci-Bresler, MD PhD, Valérie Coiteux, MD, Marc G Berger, MD PhD Professor, Lydia Roy, MD, Anne Corby, MD, Pierre-Simon Rohrlich, MDPhD, Françoise Huguet, MD, Laurence Legros, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1803.
https://doi.org/10.1182/blood.V124.21.1803.1803
Published: 2014
Journal Articles

Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study

Franck E. Nicolini, MD PhD, Nicolas Vantard, Pharm.D, Stephane Giraudier, MD PhD, Mael Heiblig, MD, Hyacinthe Johnson-Ansah, MD, Lydia Roy, MD, Claude-Eric Bulabois, MD, Denis Caillot, MD, Martine Escoffre-Barbe, MD, Eric Jourdan, MD PhD, Pascale Cony-Makhoul, MD, Agnes Guerci-Bresler, MD PhD, Laurence Legros, MD PhD, Laurent Sutton, MD, Martine Gardembas, MD, Emmanuel Gyan, MD PhD, Annelore Le Maux, Stat., Carine Guinard-Azadian, MD, Hesham Mohamed, MD, Mohamad Sobh, Pharm.M., Helene Labussiere-Wallet, MD, Gabriel Etienne, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1321.
https://doi.org/10.1182/blood.V124.21.1321.1321
Published: 2014
Journal Articles

Long Term Outcome of Chronic Phase Chronic Myeloid Leukemia (CP CML) Patients (pts) from the French Spirit Study Comparing Imatinib (IM) 400 Mg to Higher Dose Imatinib or Combination with Peg-interferonα2a (PegIFN) or Cytarabine (Ara-C) : A Trial of the FI LMC (France intergroupe de la leucemie myéloïde chronique)

Francois Guilhot, Francoise Rigal-Huguet, MD, Joelle Guilhot, PhD, Agnès Guerci-Bresler, MD, Franck E. Nicolini, MD PhD, Frédéric Maloisel, Delphine Rea, MD PhD, Valerie Coiteux, MD, Martine Gardembas, MD, Anne Vekhoff, MD, Eric Jourdan, MD PhD, Laurence Legros, MD PhD, Martine Escoffre-Barbe, MD, Philippe Rousselot, MD, Claude Preudhomme, MD PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1793.
https://doi.org/10.1182/blood.V124.21.1793.1793
Published: 2014
Journal Articles

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Franck E. Nicolini, MD, PhD, Gabriel Etienne, MD, PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, Laurence Legros, MD, PhD, Stephane Giraudier, MD, PhD, Valérie Coiteux, MD, Agnès Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, MD, PhD, Shanti Ame, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Stephane Morisset, Stat., Christine Pivot, Pharm., Madeleine Etienne, CRA, François Guilhot, MD, Stephanie Dulucq, MD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 166.
https://doi.org/10.1182/blood.V120.21.166.166
Published: 2012
Journal Articles

Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts

Delphine Rea, MD, PhD, Philippe Rousselot, MD, PhD, François Guilhot, MD, Michel Tulliez, MD, Franck E. Nicolini, MD, PhD, Agnès Guerci-Bresler, MD, Laurence Legros, MD, PhD, Martine Gardembas, MD, Stephane Giraudier, MD, PhD, Gaelle Guillerm, MD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 916.
https://doi.org/10.1182/blood.V120.21.916.916
Published: 2012
Journal Articles

Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial

Philippe Rousselot, MD, PhD, Luigina Mollica, MD, FRCPC, PhD, Gabriel Etienne, MD, PHD, Stephane Bouchet, Agnès Guerci, MD, Franck E Nicolini, MD, PhD, Emmanuelle Chauzit, MD, Pascale Cony-Makhoul, MD, Valérie Coiteux, MD, Martine Gardembas, MD, Laurence Legros, MD, PhD, Lydia Roy, MD, Aude Charbonnier, MD, PhD, Caroline Dartigeas, MD, Jean-Michel Cayuela, PhD, Lambert Busque, MD, Mathieu Molimard, MD, PhD, Joelle Guilhot, PhD, Francois Guilhot, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 3770.
https://doi.org/10.1182/blood.V120.21.3770.3770
Published: 2012
Journal Articles

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Benedicte Deau, MD, Mathias Montveneur, MStud, Valérie Coiteux, MD, Aline Renneville, MD, Francoise Rigal-Huguet, MD, Eric Delabesse, MD, PhD, Michel Tulliez, MD, Dominique Bories, MD, PhD, Aude Charbonnier, MD, PhD, Marie-Joelle Mozziconacci, MD, PhD, Thibault Legay, MD, Eric Lippert, PhD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Jean-Michel Cayuela, PhD, Shanti Amé, MD, Marie-Pierre Gaub, MD, Martine Gardembas, MD, Odile Blanchet, MD, Bruno Audhuy, MD, Agnès Buzyn, MD, PhD, Elisabeth Mac Intyre, MD, PhD, Anna-Lisa Andreoli, MD, Oumedaly Reman, Nathalie Contentin, MD, Christian Bastard, MD, Jean-Christophe Ianotto, MD, Valérie Ugo, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Said Brahimi, MD, Viviane Dubruille, Jean-Francois Brantus, MD, Mohamad Sobh, Pharm., M., Stephane Morisset, Stat., Claude Preudhomme, MD, PhD, Sandrine Hayette, PhD, Franck E Nicolini, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3378.
https://doi.org/10.1182/blood.V116.21.3378.3378
Published: 2010
Journal Articles

Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib trial): Correlation with Safety and Response.

Philippe Rousselot, MD, PhD, Stéphane Boucher, MD, PhD, Gabriel Etienne, MD, PhD, Franck E Nicolini, MD, PhD, Emmanuelle Chauzit, MD, Pascale Cony Makhoul, MD, Valérie Coiteux, MD, Agnès Guerci, MD, Martine Gardembas, MD, Laurence Legros, MD, Lydia Roy, MD, Caroline Dartigeas, MD, Maud Janvier, MD, Christian Berthou, MD, Lambert Busque, MD, FRCPC, Mathieu Molimard, MD, PhD, Joelle Guilhot, PhD, Luigina Mollica, MD, FRCPC, PhD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3432.
https://doi.org/10.1182/blood.V116.21.3432.3432
Published: 2010
Journal Articles

Phase I/II Study of Escalating Doses of Idarubicin in Combination with Methotrexate, Vindesine and Prednisolone in Patients with Primary Central Nervous System Lymphoma: Results of the GOELAMS LCP99 Multicenter Trial.

Gaelle Olivier, MD, Martine Gardembas, MD, Vincent Delwail, MD, Annie Le Mevel, MD, Martine Escoffre-Barbe, MD, Annie Brion, MD, Jean Michel Boulet, MD, Philippe Solal-Celigny, MD, Pierre Ingrand, MD, Philippe Colombat, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2694.
https://doi.org/10.1182/blood.V114.22.2694.2694
Published: 2009